Top

Published in:

01-12-2017 | Original Article

Correlations between dopamine transporter density measured by ¹²³I-FP-CIT SPECT and regional gray matter volume in Parkinson’s disease

Authors: Tomoko Maekawa, Noriko Sato, Miho Ota, Atsuhiko Sugiyama, Daichi Sone, Mikako Enokizono, Yukio Kimura, Youhei Mukai, Miho Murata, Harumasa Takano, Etsuko Imabayashi, Hiroshi Matsuda, Akira Kunimatsu, Osamu Abe

Published in: Japanese Journal of Radiology | Issue 12/2017

Abstract

Purpose

Parkinson’s disease (PD) is caused by a selective degeneration of dopamine neurons. The relationship between dopamine transporter (DAT) density and gray matter volume has been unclear. Here we investigated the voxelwise correlation between gray matter volume and DAT binding measured by ¹²³I-N-ω-fluoropropyl-2β-carboxymethoxy-3β-(4-iodophenyl)nortropane (¹²³I-FP-CIT) single-photon emission computed tomography (SPECT; DaTscan™ imaging) in PD.

Materials and methods

Thirty-one male patients with PD were examined with MRI and DaTscan. To measure nigrostriatal dopaminergic degeneration in PD, the specific binding ratio (SBR) of the striatum was obtained by DaTscan. Voxel-based morphometry (VBM) of 3D T1-weighted images was used to evaluate the relationships between the regional gray matter volume and the SBR in the striatum.

Results

There were significant positive correlations between the SBR and the gray matter volume in the right pulvinar and posterior middle temporal gyrus and a trend level in the left pulvinar, all of which are associated with the second visual pathway.

Conclusion

The nigrostriatal dopaminergic degeneration might affect the secondary visual pathway, leading to visual dysfunctions in PD.

Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–76. doi:10.1136/jnnp.2007.131045.CrossRefPubMed

Politis M. Neuroimaging in Parkinson disease: from research setting to clinical practice. Nat Rev Neurol. 2014;10(12):708–22. doi:10.1038/nrneurol.2014.205.CrossRefPubMed

Suwijn SR, van Boheemen CJ, de Haan RJ, Tissingh G, Booij J, de Bie RM. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain parkinsonism: a systematic review. EJNMMI Res. 2015;5:12. doi:10.1186/s13550-015-0087-1.CrossRefPubMedPubMedCentral

Cummings JL, Henchcliffe C, Schaier S, Simuni T, Waxman A, Kemp P. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain. 2011;134(Pt 11):3146–66. doi:10.1093/brain/awr177.CrossRefPubMed

Gerasimou G, Costa DC, Papanastasiou E, Bostanjiopoulou S, Arnaoutoglou M, Moralidis E, et al. SPECT study with I-123-ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson’s disease? Ann Nucl Med. 2012;26(4):337–44. doi:10.1007/s12149-012-0577-4.CrossRefPubMed

Burton EJ, McKeith IG, Burn DJ, Williams ED, O’Brien JT. Cerebral atrophy in Parkinson’s disease with and without dementia: a comparison with Alzheimer’s disease, dementia with Lewy bodies and controls. Brain. 2004;127(Pt 4):791–800.CrossRefPubMed

Summerfield C, Junqué C, Tolosa E, Salgado-Pineda P, Gómez-Ansón B, Martí MJ, et al. Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol. 2005;62(2):281–5.CrossRefPubMed

Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson’s disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatr. 2007;78(3):254–9.CrossRef

Melzer TR, Watts R, MacAskill MR, Pitcher TL, Livingston L, Keenan RJ, et al. Grey matter atrophy in cognitively impaired Parkinson’s disease. J Neurol Neurosurg Psychiatr. 2012;83(2):188–94. doi:10.1136/jnnp-2011-300828.CrossRef

10.

Compta Y, Ibarretxe-Bilbao N, Pereira JB, Junqué C, Bargalló N, Tolosa E, et al. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson’s disease and related dementia. Parkinsonism Relat Disord. 2012;18(8):941–7. doi:10.1016/2012.04.028 (j.parkreldis.).CrossRefPubMed

11.

Sanchez-Castaneda C, Rene R, Ramirez-Ruiz B, Campdelacreu J, Gascon J, Falcon C, et al. Correlations between gray matter reductions and cognitive deficits in dementia with Lewy Bodies and Parkinson’s disease with dementia. Mov Disord. 2009;24(12):1740–6. doi:10.1002/mds.22488.CrossRefPubMed

12.

Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson’s disease. Neuroimage. 2007;34(2):714–23.CrossRefPubMed

13.

Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology. 2008;70(16 Pt 2):1470–7.CrossRefPubMedPubMedCentral

14.

Nobili F, Arnaldi D, Campus C, Ferrara M, De Carli F, Brugnolo A, et al. Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2011;38(12):2209–18.CrossRefPubMed

15.

Choi H, Cheon GJ, Kim HJ, Choi SH, Kim YI, Kang KW, et al. Gray matter correlates of dopaminergic degeneration in Parkinson’s Disease: a hybrid PET/MR study using (18) F-FP-CIT. Hum Brain Mapp. 2016;37(5):1710–21.CrossRefPubMed

16.

Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatr. 1992;55(3):181–4.CrossRefPubMedCentral

17.

Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427–42.CrossRefPubMed

18.

Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr Staging scale: status and recommendations. Mov Disord. 2004;19(9):1020–8.CrossRefPubMed

19.

Tossici-Bolt L, Hoffmann SM, Kemp PM, Mehta RL, Fleming JS. Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging. 2006;33(12):1491–9.CrossRefPubMed

20.

Robinson DL, Petersen SE. The pulvinar and visual salience. Trends Neurosci. 1992;15(4):127–32.CrossRefPubMed

21.

Komura Y, Nikkuni A, Hirashima N, Uetake T, Miyamoto A. Responses of pulvinar neurons reflect a subject’s confidence in visual categorization. Nat Neurosci. 2013;16(6):749–55.CrossRefPubMed

22.

Danckert J, Rossetti Y. Blindsight in action: what can the different sub-types of blindsight tell us about the control of visually guided actions? Neurosci Biobehav Rev. 2005;29(7):1035–46.CrossRefPubMed

23.

Diederich NJ, Stebbins G, Schiltz C, Goetz CG. Are patients with Parkinson’s disease blind to blindsight? Brain. 2014;137(Pt 6):1838–49. doi:10.1093/brain/awu094.CrossRefPubMedPubMedCentral

24.

Ku J, Kim JJ, Jung YC, Park IH, Lee H, Han K, et al. Brain mechanisms involved in processing unreal perceptions. Neuroimage. 2008;43(4):793–800. doi:10.1016/j.neuroimage.2008.08.011.CrossRefPubMed

25.

Boecker H, Ceballos-Baumann AO, Volk D, Conrad B, Forstl H, Haussermann P. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol. 2007;64(7):984–8.CrossRefPubMed

26.

Zeki S, Watson JD, Lueck CJ, Friston KJ, Kennard C, Frackowiak RS. A direct demonstration of functional specialization in human visual cortex. J Neurosci. 1991;11(3):641–9.PubMed

27.

Tootell RB, Reppas JB, Kwong KK, Malach R, Born RT, Brady TJ, et al. Functional analysis of human MT and related visual cortical area using magnetic resonance imaging. J Neurosci. 1995;15(4):3215–30.PubMed

Title: Correlations between dopamine transporter density measured by 123I-FP-CIT SPECT and regional gray matter volume in Parkinson’s disease
Authors: Tomoko Maekawa
Noriko Sato
Miho Ota
Atsuhiko Sugiyama
Daichi Sone
Mikako Enokizono
Yukio Kimura
Youhei Mukai
Miho Murata
Harumasa Takano
Etsuko Imabayashi
Hiroshi Matsuda
Akira Kunimatsu
Osamu Abe
Publication date: 01-12-2017
Publisher: Springer Japan
Published in: Japanese Journal of Radiology / Issue 12/2017
Print ISSN: 1867-1071
Electronic ISSN: 1867-108X
DOI: https://doi.org/10.1007/s11604-017-0694-z

At a glance: The STEP trials

Springer Medicine

Correlations between dopamine transporter density measured by ¹²³I-FP-CIT SPECT and regional gray matter volume in Parkinson’s disease

Abstract

Purpose

Materials and methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2017

The spectrum of imaging appearances of müllerian duct anomalies: focus on MR imaging

Hooking intestine sign: a typical diagnostic CT finding of Petersen’s hernia

Prognostic value of volumetric FDG PET/CT parameters in patients with oral tongue squamous cell carcinoma who were treated by superselective intra-arterial chemoradiotherapy

A novel utility of 99mTc-GSA SPECT/CT fusion imaging: detection of inadequate portal vein embolization

Value of three-dimensional T2-weighted turbo spin-echo imaging with tissue-specific variable refocusing flip angle for 3-T magnetic resonance imaging of prostate cancer: comparison with conventional two- and three-dimensional T2-weighted turbo spin-echo imaging

Comparison of changes in renal function with dosimetric parameters in gastric cancer patients treated with adjuvant chemoradiotherapy